Behind today’s rapidly expanding clinical pipelines, CMC has emerged as one of the most critical factors determining whether an ADC can successfully reach the market. Recent FDA setbacks involving Chinese ADC assets have drawn significant industry attention, highlighting that CMC is no longer simply a back-office function, but a strategic priority that can influence company valuations, BD deal terms and long-term global competitiveness. Co-hosted by Healthcare Executive, Weijieyao, Asymchem and AsymBio, this panel brings together biotech executives and industry leaders from around the world to examine how CMC and manufacturing strategy influence an ADC’s path to commercial supply and global markets—covering manufacturing models, global regulatory compliance, supply-chain resilience and long-term competitiveness. What We Will CoverCMC – The Invisible Arbiter of ADC CommercializationThe Crossroads of Manufacturing Strategy – In-House, CDMO, or Hybrid?Global CMC Compliance – Navigating Regulatory Expectations Across MarketsSupply Chain Resilience – From Cost Efficiency to Strategic SecurityLooking Ahead – How CMC Will Shape the Next Generation of ADC Leaders September 29, 2026 11:00 AM ET | 8:00 AM PTCo-hosted by Healthcare Executive, Weijieyao, Asymchem and AsymBioRegistration is now open: Click to Register

AsymBio is heading to Boston for the Oncology & Immunology Innovation Partnering & Licensing Summit, September 9–10!We look forward to connecting with industry partners and exploring new opportunities in oncology and immunology.Scan the QR code to schedule a meeting with our team.See you in Boston!

Webinar Invitation: Phase-Appropriate Development and CMC Control Strategies of Biologics and ADCs The structural complexity of biologics and ADCs creates significant challenges in development and quality control. How can development teams apply the right level of CMC rigor at each phase while maintaining efficiency? Join our upcoming webinar to explore a phased, QbD- and risk-based approach to biologics and ADC development and CMC control. Key Learning Objectives:1. The principles of QbD-based CMC development strategy2. Phase-appropriate development strategy for CQA, specifications, analytical methods, process change and comparability3. Highlights of AsymBio’s growing global presence Speaker Dr. Zhaofeng DingExecutive Director, CMC Lead, AsymBio 15+ years of pharmaceutical development experience in the U.S. and China, with 50+ INDs and 10+ NDA/BLAs led and filed across mAbs, bsAbs, fusion proteins, ADCs and polypeptides. Click to Register

Webinar Invitation: Overcoming the Challenges in ADC Drug Product Development by Leveraging an Integrated PlatformAs antibody-drug conjugates (ADCs) continue to evolve with increasingly diverse antibody, linker, and payload designs, drug product (DP) development has become more complex than ever. Achieving a robust and scalable DP strategy requires balancing formulation, stability, manufacturing, dosage form, and clinical administration while addressing the unique characteristics of each ADC molecule.How can you overcome key drug product development challenges while accelerating development and ensuring product quality from early-stage development through commercialization?Join our upcoming webinar to explore practical strategies, integrated platform capabilities, and real-world case studies that support successful ADC drug product development in a CDMO environment.Key Learning ObjectivesCommon challenges in ADC drug product developmentStrategies to mitigate light- and oxidation-induced degradation of ADCsOptimization of lyophilized ADC drug product formulationsCustomized in-use evaluations to support clinical administrationSpeaker Shujing Wang Head of Drug Product Development, AsymBioClick to Register

We are thrilled to announce AsymBio’s partnership with the 4th ADC Linker & Conjugation Summit, taking place July 28–30, 2026 in Boston, MA — the industry’s premier gathering focused on payload-linker , bioconjugation, and next-gen ADC. Our team will be on-site to showcase AsymBio’s award winning Conjugation Toolbox. Backed by in-house payload-linker and antibody CMC capabilities, we deliver integrated solutions covering early-stage development through clinical and commercial ADC manufacturing. Connect with our team to shape the future of ADC together. See you in Boston!

AsymBio is proud to be an Exhibition Partner at the 5th Targeted Radiopharmaceuticals Summit US in San Diego (July 21–23, 2026)! AsymBio is the leading CDMO solutions provider in RDC landscape — from process development to late-stage CMC. Visit us at our booth to learn how AsymBio supports partners across the radiopharmaceutical journey with integrated services that accelerate progress from molecule to market.

Webinar Invitation: Developing Efficient Downstream Purification for Bispecific Antibodies: Challenges and BreakthroughsAs bispecific antibodies continue to gain momentum across the biopharmaceutical landscape, efficient downstream purification is essential for achieving high product quality, manufacturing consistency, and scalable production.How can you overcome purification challenges such as aggregation, impurity removal, and process compatibility while improving downstream process efficiency?Join our upcoming webinar to explore practical strategies and enabling technologies for optimizing downstream purification of bispecific antibodies.Key Learning ObjectivesThe value and prospects of bispecific antibodiesChallenges in downstream process development and large scale productionCase study and strategies for Asymmetric bispecific antibodyStrategies of viral clearance studiesSpeakerPuya ZhaoSenior Director, Downstream Process Development, AsymBioClick to Register

At ASCO 2026, China-led ADC studies reached a new milestone, outnumbering U.S.-led studies for the first time.Is this a milestone - or the beginning of a broader shift in global oncology innovation?To explore this question, we are excited to launch the inaugural episode of China BioPioneers · International Edition—a new online panel series dedicated to fostering deeper dialogue between Chinese innovators and global industry leaders.Co-hosted by AsymBio, Asymchem Group, iSWT Community, Healthcare Executive, and Weijieyao, the series explores the ideas, innovations, and partnerships shaping the future of biopharma.Our first panel will bring together leaders from Merck, Orum Therapeutics, XYone Therapeutics, and leading Chinese biotechs MediLink Therapeutics and Lepu Biopharma to discuss:China–West Perspectives on Innovation, Globalization, and the Next Wave of ADC DevelopmentJuly 1, 2026 | 11:00 AM ETRegistration is now open: Click to Register

China’s radiopharmaceutical industry is entering a pivotal stage of growth, bringing unprecedented opportunities alongside new challenges across supply, manufacturing, clinical development, and commercialization.Join us on June 12 as experts from industry, academia, healthcare, and investment come together to share perspectives, exchange ideas, and explore how collaboration can help accelerate innovation and support the global advancement of China’s radiopharmaceutical sector.Date: June 12, 2026Panel Discussion: 1:00–6:00 PM (CST)Networking Dinner: 6:00–8:30 PM (CST)Muly Coffee & Bistro, Zhangjiang, Shanghai

Webinar Invitation | Key Considerations for an Effective CMC Development Strategy in ADC ProjectsAs ADCs continue to transform cancer treatment, the complexity of their development presents unique Chemistry, Manufacturing, and Controls (CMC) challenges. From conjugation strategy and analytical characterization to formulation development and regulatory planning, every CMC decision can have a significant impact on product quality, development timelines, and commercial success.How can teams build an effective CMC strategy that balances speed, quality, and scalability throughout ADC development? Join our upcoming webinar to explore key considerations and practical approaches for advancing ADC programs from early development through commercialization.Key Topics Include:Conjugation platform selection and its impact on DAR control and product homogeneity Analytical method development for complex ADC characterization Formulation and stability strategiesRegulatory and scalability considerationsSpeakerTiejun Li, PhDVice General Manager, Head of CMC and PM, AsymBioClick to Register